United States · Series C startup
One round we have observed, with the 6 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.
Funding summaryUpdated 26 Oct 2026
$73Mraised across 1 round since 2023, from 1 source
Missing a round, or an investor who was in one? Tell us.
Myeloid Therapeutics, Inc.'s investors include Hatteras Venture Partners, 8VC, ARCH Venture Partners, Alexandria Real Estate Equities and Moore Strategic Ventures, and 1 more on record. Hatteras Venture Partners led its latest round.
Myeloid Therapeutics, Inc. has raised $73M across 1 round since 2023.
Myeloid Therapeutics, Inc.'s most recent round was a Series C of $73M in May 2023, led by Hatteras Venture Partners.
Its most recent round, $73M in May 2023, is also its largest on record.
Myeloid Therapeutics, Inc.'s first round on record, in May 2023, was backed by Hatteras Venture Partners, 8VC and ARCH Venture Partners and 3 others.
Myeloid Therapeutics, Inc.'s latest named round is a Series C, in May 2023.
Myeloid Therapeutics, Inc. is based in the United States.
Hatteras Venture Partners led the Series C in 2023.
In the same sector, and raised in the last eighteen months.
Search every investor by what they have actually funded, then narrow to your stage and market. Free.
United States · 
